filanesib + dexamethasone

Filanesib + dexamethasone is an investigational combination therapy for relapsed or refractory multiple myeloma and other hematologic malignancies. Filanesib (ARRY-520) is a highly selective small molecule inhibitor of **kinesin spindle protein (KSP, Eg5)**, an essential protein for mitosis. By inhibiting KSP, filanesib induces cell cycle arrest and apoptosis in cancer cells, especially those dependent on the anti-apoptotic protein MCL-1. Dexamethasone is a glucocorticoid with anti-inflammatory and antineoplastic activity, often used in combination therapy in multiple myeloma. The combination has been studied in heavily pretreated patients, showing modest clinical activity and a manageable safety profile, with main toxicities being cytopenias and mucositis[1][4][7][8][9].

Other names

ARRY-520 + dexamethasonefilanesib + dexamethasone